Donor-transmitted diseases

Liver Transplantation

Volumn 16, Issue SUPPL. 2, 2010, Pages

  Teperman, Lewis ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DISEASE TRANSMISSION; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS 2; LYMPHOMA; ORGAN DONOR; PRIORITY JOURNAL; VIRUS TRANSMISSION; WEST NILE FLAVIVIRUS;

EID: 78651382122     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.22153     Document Type: Article

References (25)

1. Buell JF, Beebe TM, Trofe J, Gross TG, Alloway RR, Hanaway MJ, et al. Donor transmitted malignancies. Ann Transplant 2004; 9: 53-56.
2. Ison MG, Hager J, Blumberg E, Burdick J, Carney K, Cutler J, et al. Donor-derived disease transmission events in the United States: data reviewed by the OPTN/UNOS Disease Transmission Advisory Committee. Am J Transplant 2009; 9: 1929-1935.
3. Nalesnik M, Woodle E, DiMaio J, Vasudev B, Teperman L, Covington S, et al. Donor transmitted malignancies in organ transplantation: assessment of clinical risk. Report of the ad hoc Donor Malignancy Subcommittee of the OPTN/UNOS Disease Transmission Advisory Committee. In press.
4. Organ Procurement and Transplantation Network. Policy 2: Minimum Procurement Standards for an Organ Procurement Organization (OPO). Rockville, MD: US Department of Health and Human Services; 2009.
5. United Network for Organ Sharing. Accessed July 2010.
6. Harbell JW, Dunn TB, Fauda M, John DG, Goldenberg AS, Teperman LW., Transmission of anaplastic large cell lymphoma via organ donation after cardiac death. Am J Transplant 2008; 8: 238-244.
7. Singer AL, Kucirka LM, Namuyinga R, Hanrahan C, Subramanian AK, Segev DL., The high-risk donor: viral infections in solid organ transplantation. Curr Opin Organ Transplant 2008; 13: 400-404.
8. Grady D., Four transplant recipients contract H.I.V. New York Times November 13, 2007.
9. Gastaca M., Extended criteria donors in liver transplantation: adapting donor quality and recipient. Transplant Proc 2009; 41: 975-979.
10. Busuttil RW, Tanaka K., The utility of marginal donors in liver transplantation. Liver Transpl 2003; 9: 651-663. (Pubitemid 36874450)
11. Ghobrial RM, Steadman R, Gornbein J, Lassman C, Holt CD, Chen P, et al. A 10-year experience of liver transplantation for hepatitis C: analysis of factors determining outcome in over 500 patients. Ann Surg 2001; 234: 384-393. (Pubitemid 32847075)
12. Khapra AP, Agarwal K, Fiel MI, Kontorinis N, Hossain S, Emre S, et al. Impact of donor age on survival and fibrosis progression in patients with hepatitis C undergoing liver transplantation using HCV+ allografts. Liver Transpl 2006; 12: 1496-1503. (Pubitemid 44594280)
13. Saab S, Ghobrial RM, Ibrahim AB, Kunder G, Durazo F, Han S, et al. Hepatitis C positive grafts may be used in orthotopic liver transplantation: a matched analysis. Am J Transplant 2003; 3: 1167-1172. (Pubitemid 37064557)
14. Marroquin CE, Marino G, Kuo PC, Plotkin JS, Rustgi VK, Lu AD, et al. Transplantation of hepatitis C-positive livers in hepatitis C-positive patients is equivalent to transplanting hepatitis C-negative livers. Liver Transpl 2001; 7: 762-768. (Pubitemid 32851295)
15. Dodson SF, Issa S, Araya V, Gayowski T, Pinna A, Eghtesad B, et al. Infectivity of hepatic allografts with antibodies to hepatitis B virus. Transplantation 1997; 64: 1582-1584. (Pubitemid 28047387)
16. Hashimoto K, Miller C., The use of marginal grafts in liver transplantation. J Hepatobiliary Pancreat Surg 2008; 15: 92-101. (Pubitemid 351516966)
17. Burton JR Jr, Shaw-Stiffel TA., Use of hepatitis B core antibody-positive donors in recipients without evidence of hepatitis B infection: a survey of current practice in the United States. Liver Transpl 2003; 9: 837-842.
18. Teperman L, Spivey J, Poordad F, Schiano TD, Bzowej N, Pungpapong S, et al. A randomized trial of HBIG withdrawal using emtricitabine/tenofovir DF in post-orthotopic liver transplant recipients. Liver Transpl. In press.
19. Perrillo RP, Eason JD., The use of HBsAg-positive organ donors: far more than meets the eye? Liver Transpl 2005; 11: 875-877.
20. Martin-Davila P, Fortun J, Lopez-Velez R, Norman F, Montes de Oca M, Zamarron P, et al. Transmission of tropical and geographically restricted infections during solid-organ transplantation. Clin Microbiol Rev 2008; 21: 60-96. (Pubitemid 351160010)
21. Iwamoto M, Jernigan DB, Guasch A, Trepka MJ, Blackmore CG, Hellinger WC, et al. Transmission of West Nile virus from an organ donor to four transplant recipients. N Engl J Med 2003; 348: 2196-2203. (Pubitemid 36618130)
22. Teperman L, Diflo T, Fahmy A, GR, Morgan, Wetherbee RE, Ratner L, et al. West Nile virus infections in organ transplant recipients-New York and Pennsylvania, August-September, 2005. MMWR Morb Mortal Wkly Rep 2005; 54: 1021-1023.
23. Kaul DR, Taranto S, Alexander C, Covington S, Marvin M, Nowicki M, et al. Donor screening for human T-cell lymphotrophic virus 1/2: changing paradigms for changing testing capacity. Am J Transplant 2010; 10: 207-213.
24. Ison MG., The epidemiology and prevention of donor-derived infections. Adv Chronic Kidney Dis 2009; 16: 234-241.
25. Humar A, Morris M, Blumberg E, Freeman R, Preiksaitis J, Kiberd B, et al. Nucleic acid testing (NAT) of organ donors: is the 'best' test the right test? A consensus conference report. Am J Transplant 2010; 10: 889-899.